Drug holiday of high-dose denosumab and recovery from osteoclast inhibition using immunohistochemical investigation of 7 patients with medication-related osteonecrosis of the jaw undergoing segmental mandibulectomy
Background/purpose: Denosumab is used to treat bone metastases from malignant tumors. Unlike bisphosphonates, denosumab is not deposited in the bone; thus, withdrawal for a relatively short period would help recovery from osteoclast suppression. This study investigated the relationship between drug...
Saved in:
Main Authors: | Shunsuke Sawada (Author), Yuki Sakamoto (Author), Mako Kirihigashi (Author), Yuka Kojima (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A preliminary clinical study of segmental mandibulectomy on medication-related osteonecrosis of the jaw
by: Mitsunobu Otsuru, et al.
Published: (2022) -
DENOSUMAB-RELATED OSTEONECROSIS OF THE JAWS: A CASE REPORT
by: Milena Petkova, et al.
Published: (2017) -
Denosumab Related Osteonecrosis of Jaw: a Case Report
by: Marco Vinícius de Sales Lima, et al.
Published: (2018) -
Posible denosumab-induced jaw osteonecrosis in the treatment of osteoporosis. A case report
by: P. Selvi Sabater, et al.
Published: (2014) -
Case series: Osteonecrosis of the jaw related to denosumab preceded by bisphosphonates in cancer and osteoporotic patients
by: Devie Falinda, et al.
Published: (2022)